Channing J Paller1, Emmanuel S Antonarakis1, Tomasz M Beer2, Hala T Borno3, Maria I Carlo4, Daniel J George5, Julie N Graff6, Shilpa Gupta7, Elisabeth I Heath8, Celestia S Higano9, Rana R McKay10, Alicia K Morgans11, Akash Patnaik12, Daniel P Petrylak13, Matthew B Rettig14, Charles J Ryan7, Mary-Ellen Taplin15, Young E Whang16, Jacob Vinson17, Heather H Cheng18, Veda N Giri19. 1. Sidney Kimmel Comprehensive Cancer Center, Department of Urology, Johns Hopkins University, Baltimore, MD. 2. Division of Hematology/Medical Oncology School of Medicine, Oregon Health and Science University Knight Cancer Institute, Portland, OR. 3. Department of Medicine, University of California San Francisco/Helen Diller Family Cancer, San Francisco, CA. 4. Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Division of Medical Oncology, Department of Medicine and Duke Cancer Institute, Duke University Medical Center, Durham, NC. 6. Division of Hematology and Medical Oncology, VA Portland Health Care System/Oregon Health & Science University Knight Cancer Institute, Portland, OR. 7. Division of Hematology, Oncology, and Transplantation, University of Minnesota Masonic Cancer Center, Minneapolis, MN. 8. Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI. 9. Fred Hutchinson Cancer Research Center and Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA. 10. Department of Medicine, University of California at San Diego Moores Cancer Center, La Jolla, CA. 11. Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine at Northwestern University, Chicago, IL. 12. Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL. 13. Department of Urology, Yale Cancer Center, New Haven, CT. 14. Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA. 15. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA. 16. Department of Medicine, Hematology/Oncology, University of North Carolina Lineberger Cancer Center, Chapel Hill, NC. 17. Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, New York, NY. 18. Fred Hutchinson Cancer Research Center and Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA. Electronic address: hhcheng@uw.edu. 19. Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA. Electronic address: Veda.Giri@jefferson.edu.
Abstract
BACKGROUND: Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provide guidance and resources to expand effective use of germline genetic testing. MATERIALS AND METHODS: A 14-item questionnaire was e-mailed to academic oncologists at 43 PCCTC sites to collect information on germline genetic testing patterns, including patients considered, choice of assays, barriers slowing adoption, and actions to overcome barriers. RESULTS: Twenty-six genitourinary oncologists from 19 institutions responded. Less than 40% (10 of 26) reported referring patients to a genetics department, whereas the remainder take personal responsibility for genetic testing and counseling; 16 (62%) consider testing all metastatic PCa patients, whereas 3 (12%) consider testing all patients with high-risk local disease; and 7 (27%) use multigene comprehensive pan-cancer panels, and 14 (54%) use smaller or targeted cancer gene panels. Barriers to widespread use are: (1) delayed or limited access to genetic counseling; (2) no insurance coverage; (3) lack of effective workflows; (4) insufficient educational materials; and (5) time and space constraints in busy clinics. The primary limitation was the <50% (19 of 43) response from PCCTC sites and no coverage of nonacademic cancer treatment facilities. CONCLUSION: Joint efforts by urologists, oncologists, genetics counselors, insurers, and cancer centers can accelerate implementation of integrated germline genetic services for personalized treatment and clinical trial eligibility for PCa patients.
BACKGROUND: Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provide guidance and resources to expand effective use of germline genetic testing. MATERIALS AND METHODS:A 14-item questionnaire was e-mailed to academic oncologists at 43 PCCTC sites to collect information on germline genetic testing patterns, including patients considered, choice of assays, barriers slowing adoption, and actions to overcome barriers. RESULTS: Twenty-six genitourinary oncologists from 19 institutions responded. Less than 40% (10 of 26) reported referring patients to a genetics department, whereas the remainder take personal responsibility for genetic testing and counseling; 16 (62%) consider testing all metastatic PCa patients, whereas 3 (12%) consider testing all patients with high-risk local disease; and 7 (27%) use multigene comprehensive pan-cancer panels, and 14 (54%) use smaller or targeted cancer gene panels. Barriers to widespread use are: (1) delayed or limited access to genetic counseling; (2) no insurance coverage; (3) lack of effective workflows; (4) insufficient educational materials; and (5) time and space constraints in busy clinics. The primary limitation was the <50% (19 of 43) response from PCCTC sites and no coverage of nonacademic cancer treatment facilities. CONCLUSION: Joint efforts by urologists, oncologists, genetics counselors, insurers, and cancer centers can accelerate implementation of integrated germline genetic services for personalized treatment and clinical trial eligibility for PCa patients.
Authors: Veda N Giri; Sarah E Hegarty; Colette Hyatt; Erin O'Leary; John Garcia; Karen E Knudsen; William K Kelly; Leonard G Gomella Journal: Prostate Date: 2018-11-18 Impact factor: 4.104
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: Jennifer M Hoskovec; R L Bennett; M E Carey; J E DaVanzo; M Dougherty; S E Hahn; B S LeRoy; S O'Neal; J G Richardson; C A Wicklund Journal: J Genet Couns Date: 2017-10-20 Impact factor: 2.537
Authors: Francesco Cantiello; Fabio Crocerossa; Giorgio Ivan Russo; Vincenzo Gangemi; Matteo Ferro; Mihai Dorin Vartolomei; Giuseppe Lucarelli; Maria Mirabelli; Chiara Scafuro; Giuseppe Ucciero; Ottavio De Cobelli; Giuseppe Morgia; Rocco Damiano; Giuseppe Lucio Cascini Journal: Clin Genitourin Cancer Date: 2018-06-04 Impact factor: 2.872
Authors: Andrea K Miyahira; Kenneth J Pienta; Michael J Morris; Neil H Bander; Richard P Baum; Wolfgang P Fendler; William Goeckeler; Michael A Gorin; Hartwig Hennekes; Martin G Pomper; Oliver Sartor; Scott T Tagawa; Scott Williams; Howard R Soule Journal: Prostate Date: 2018-05-01 Impact factor: 4.104
Authors: Maria I Carlo; Veda N Giri; Channing J Paller; Wassim Abida; Joshi J Alumkal; Tomasz M Beer; Himisha Beltran; Daniel J George; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Charles J Ryan; Edward M Schaeffer; Walter M Stadler; Mary-Ellen Taplin; Noah D Kauff; Jacob Vinson; Emmanuel S Antonarakis; Heather H Cheng Journal: JCO Precis Oncol Date: 2018-08-16
Authors: Martin G Sanda; Jeffrey A Cadeddu; Erin Kirkby; Ronald C Chen; Tony Crispino; Joann Fontanarosa; Stephen J Freedland; Kirsten Greene; Laurence H Klotz; Danil V Makarov; Joel B Nelson; George Rodrigues; Howard M Sandler; Mary Ellen Taplin; Jonathan R Treadwell Journal: J Urol Date: 2017-12-15 Impact factor: 7.450
Authors: Jacob E Berchuck; Daniel Boiarsky; Rebecca Silver; Rajitha Sunkara; Heather M McClure; Harrison K Tsai; Stephanie Siegmund; Alok K Tewari; Jonathan A Nowak; Neal I Lindeman; Huma Q Rana; Atish D Choudhury; Mark M Pomerantz; Matthew L Freedman; Eliezer M Van Allen; Mary-Ellen Taplin Journal: JCO Precis Oncol Date: 2022-08
Authors: Brittany M Szymaniak; Lauren A Facchini; Veda N Giri; Emmanuel S Antonarakis; Tomasz M Beer; Maria I Carlo; Daniel C Danila; Mallika Dhawan; Daniel George; Julie N Graff; Shilpa Gupta; Elisabeth Heath; Celestia S Higano; Glenn Liu; Ana M Molina; Channing J Paller; Akash Patnaik; Daniel P Petrylak; Zachery Reichert; Matthew B Rettig; Charles J Ryan; Mary-Ellen Taplin; Jake Vinson; Young E Whang; Alicia K Morgans; Heather H Cheng; Rana R McKay Journal: JCO Oncol Pract Date: 2020-09-28
Authors: Jessica Russo; Carey McDougall; Nicholas Bowler; Ayako Shimada; Laura Gross; Colette Hyatt; William K Kelly; Anne Calvaresi; Nathan R Handley; Irvin H Hirsch; Joseph K Izes; Costas D Lallas; Mark Mann; James Ryan Mark; Patrick J Mille; Donald Preate; Edouard J Trabulsi; Miranda Tsang; Thenappan Chandrasekar; Perry R Weiner; Leonard G Gomella; Veda N Giri Journal: JCO Precis Oncol Date: 2021-09-01
Authors: Peter K F Chiu; Eric K C Lee; Marco T Y Chan; Wilson H C Chan; M H Cheung; Martin H C Lam; Edmond S K Ma; Darren M C Poon Journal: Front Oncol Date: 2022-07-18 Impact factor: 5.738
Authors: Shouki Bazarbashi; Wen-Pin Su; Siew W Wong; Ramanujam A Singarachari; Sudhir Rawal; Maria I Volkova; Diogo A Bastos Journal: Oncol Ther Date: 2021-07-08
Authors: Veda N Giri; Karen E Knudsen; William K Kelly; Heather H Cheng; Kathleen A Cooney; Michael S Cookson; William Dahut; Scott Weissman; Howard R Soule; Daniel P Petrylak; Adam P Dicker; Saud H AlDubayan; Amanda E Toland; Colin C Pritchard; Curtis A Pettaway; Mary B Daly; James L Mohler; J Kellogg Parsons; Peter R Carroll; Robert Pilarski; Amie Blanco; Ashley Woodson; Alanna Rahm; Mary-Ellen Taplin; Thomas J Polascik; Brian T Helfand; Colette Hyatt; Alicia K Morgans; Felix Feng; Michael Mullane; Jacqueline Powers; Raoul Concepcion; Daniel W Lin; Richard Wender; James Ryan Mark; Anthony Costello; Arthur L Burnett; Oliver Sartor; William B Isaacs; Jianfeng Xu; Jeffrey Weitzel; Gerald L Andriole; Himisha Beltran; Alberto Briganti; Lindsey Byrne; Anne Calvaresi; Thenappan Chandrasekar; David Y T Chen; Robert B Den; Albert Dobi; E David Crawford; James Eastham; Scott Eggener; Matthew L Freedman; Marc Garnick; Patrick T Gomella; Nathan Handley; Mark D Hurwitz; Joseph Izes; R Jeffrey Karnes; Costas Lallas; Lucia Languino; Stacy Loeb; Ana Maria Lopez; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark Mann; Patrick Mille; Martin M Miner; Todd Morgan; Jose Moreno; Lorelei Mucci; Ronald E Myers; Sarah M Nielsen; Brock O'Neil; Wayne Pinover; Peter Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Charles Ryan; Howard Sandler; Matthew Schiewer; E Michael D Scott; Brittany Szymaniak; William Tester; Edouard J Trabulsi; Neha Vapiwala; Evan Y Yu; Charnita Zeigler-Johnson; Leonard G Gomella Journal: J Clin Oncol Date: 2020-06-09 Impact factor: 44.544
Authors: Roderick Clark; Miran Kenk; Kristen McAlpine; Emily Thain; Kirsten M Farncombe; Colin C Pritchard; Robert Nussbaum; Alexander W Wyatt; Johann de Bono; Danny Vesprini; Yvonne Bombard; Justin Lorentz; Steven Narod; Raymond Kim; Neil Fleshner Journal: Can Urol Assoc J Date: 2021-12 Impact factor: 1.862